What Matters Now
CME
Optimizing Comprehensive Molecular Profiling in Advanced NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Anna-Lena Meinhardt, M.D., Ph.D., National Cancer Institute
90% of Peers Changed Their Practice After this Clinical Scenario
CME
Distinguishing treatment-related pneumonitis from infection or disease progression in a patient with metastatic HER2-mutant NSCLC on HER2-directed therapy.
What Matters Now
CME
Optimizing Comprehensive Molecular Profiling in Advanced NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Anna-Lena Meinhardt, M.D., Ph.D., National Cancer Institute
Corresponding Scenario
New Respiratory Symptoms on HER2-Targeted Therapy: What Is the Next Step?
See experiences from 255 peers
Distinguishing treatment-related pneumonitis from infection or disease progression in a patient with metastatic HER2-mutant NSCLC on HER2-directed therapy.
How clinicians responded after this Clinical Scenario
66
%
begin unsure how to apply evidence
90
%
will implement a practice change
